ArticleNeuro-oncology2026
Erratum to: High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.